Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
68,083.88 +443.71 (+0.66%) CMC Crypto 200
1,433.08 +4.51 (+0.32%)
NBIX Dec 2024 150.000 put
| Previous close | 20.00 |
| Open | 20.00 |
| Bid | 16.10 |
| Ask | 18.90 |
| Strike | 150.00 |
| Expiry date | 2024-12-20 |
| Day's range | 20.00 - 20.00 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
PR NewswireNeurocrine Biosciences to Participate at Investor Conferences in June
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in June.
- PR Newswire
Neurocrine Biosciences Announces CEO Succession Plan
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that Kevin Gorman, Ph.D., will retire as Chief Executive Officer of Neurocrine on October 11, 2024. Kyle Gano, Ph.D., currently Neurocrine's Chief Business Development and Strategy Officer, will succeed him in the CEO role. Dr. Gano will also join the Company's Board of Directors at that time, and Dr. Gorman will continue to serve on the Neurocrine Board.
- PR Newswire
Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its neuroendocrinology pipeline, including new Phase 3 clinical study data from its CAHtalyst™ registrational studies of crinecerfont in pediatric and adult patients with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency and data from its modified-release hydrocortisone (MRHC) studies in primary adrenal insufficiency and CAH. These data, along with several additional
